New approaches in glioblastoma multiforme: the potential role of immune-check point inhibitors.

New approaches in glioblastoma multiforme: the potential role of immune-check point inhibitors.

Curr Cancer Drug Targets. 2016 Aug 13;

Authors: De Felice F, Musio D, Cassese R, Gravina GL, Tombolini V

Abstract
BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response.
OBJECTIVE: To clarify the role of immune check point inhibitors in GBM management.
METHODS: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials.gov and abstracts recently presented at international congresses.
RESULTS: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management.
CONCLUSION: Immune check-point inhibitors should be considered a promising treatment option in GBM.

PMID: 27528363 [PubMed - as supplied by publisher]

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2bC7BmK
via IFTTT